Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis

doi:10.5314/wjd.121180

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

(2)

(0)

(23)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Dermatology

ISSN

2218-6190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Dermatol. Sep 16, 2026; 12(1): 121180
Published online Sep 16, 2026. doi: 10.5314/wjd.121180

Table 1 Demographic and clinical characteristics of the patients included in the study, n (%)/median (inter-quartile range)/median ± inter-quartile range

	Secukinumab	Guselkumab	P value
Number of patients	87 (58.4)	62 (41.6)	-
Age (years)	53.7 (11.8-18.5)	50.1 (11.2-17.9)	NR
Male sex	40 (46.0)	41 (66.1)	0.023
PAS	15.0 (12.1-17.9)	15.4 (13.7-17.1)	NR
DLQI	12.9 (8.6-17.2)	12.4 (4.6-20.2)	NR
Non-Naïve	43 (49.4)	44 (70.9)	0.014
Previous lines of treatment	1.4 ± 0.8	1.9 ± 0.9	NR

P values calculated using χ² test for categorical variables. DLQI: Dermatology life quality index; PASI: Psoriasis Areas and Severity Index, IQR: Inter-quartile range; NR: Not reported.

Full Size Table

Table 2 Survival function at years 1, 2, 3, 4 and 5 for patients receiving secukinumab and guselkumab

Drug	Measure	12 months	24 months	36 months	48 months	60 months
Secukinumab (n = 87)	Patients on treatment/number of discontinuations	62/5	43/4	34/5	25/3	15/1
Secukinumab (n = 87)	Survival function (95%CI)	82.8 (74.6-91.0)	75.3 (65.5-85.0)	67.9 (56.7-79.0)	57.3 (44.5-70.0)	49.3 (35.5-63.1)
Guselkumab (n = 62)	Patients on treatment/number of discontinuations	50/2	23/1	11/0	3/0	-
Guselkumab (n = 62)	Survival function (95%CI)	98.2 (94.8-100)	93.0 (85.2-100)	87.7 (75.2-100)	87.7 (79.5-95.9)	-

Full Size Table

Citation: Borrás-Blasco J, Valcuende-Rosique A, Alcala R, Cornejo-Uixeda S. Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis. World J Dermatol 2026; 12(1): 121180
URL: https://www.wjgnet.com/2218-6190/full/v12/i1/121180.htm
DOI: https://dx.doi.org/10.5314/wjd.121180

Borrás-Blasco J, Valcuende-Rosique A, Alcala R, Cornejo-Uixeda S. Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis. World J Dermatol 2026; 12(1): 121180 [DOI: 10.5314/wjd.121180]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.